Chapel Hill, NC, United States of America

Hongwei Du

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Hongwei Du in Cancer Treatment

Introduction

Hongwei Du is a prominent inventor based in Chapel Hill, NC (US). He has made significant contributions to the field of cancer treatment through his innovative work on chimeric antigen receptors. With a total of 2 patents, his research focuses on developing methods and compositions that target cancer cells effectively.

Latest Patents

Hongwei Du's latest patents include groundbreaking inventions that provide a chimeric antigen receptor (CAR) recognizing B7-H3 (CD276). These inventions offer promising methods of use in the treatment of various diseases and disorders, particularly in oncology. His work aims to enhance the efficacy of cancer therapies by utilizing advanced immunological techniques.

Career Highlights

Throughout his career, Hongwei Du has been associated with esteemed institutions such as the University of North Carolina at Chapel Hill and The General Hospital Corporation. His work in these organizations has allowed him to collaborate with leading experts in the field, further advancing his research and innovations.

Collaborations

Some of his notable coworkers include Gianpietro Dotti and Soldano Ferrone. Their collaborative efforts have contributed to the development of innovative solutions in cancer treatment, showcasing the importance of teamwork in scientific research.

Conclusion

Hongwei Du's contributions to cancer treatment through his innovative patents and collaborations highlight the potential of chimeric antigen receptors in modern medicine. His work continues to inspire advancements in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…